Hospital
Livingston Healthcare
Livingston Healthcare was paid $1.17M by Medicaid between Jan 2018 and Dec 2024, across 135 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoLIVINGSTON HEALTHCARE
LIVINGSTON, MT 59047
LIVINGSTON, MT 59047
33aNPI1245222306assigned 08/16/2005
33bProvider typeCritical Access Hospital
28Total paid$1.17M
24GClaims175,546
24DCodes billed135
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Montana
Rank by total paid#2 of 25
Median peer was paid$185K
This provider vs. median6.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,905 | $210K | |
| 2019 | 26,749 | $199K | |
| 2020 | 23,351 | $114K | |
| 2021 | 27,272 | $101K | |
| 2022 | 27,976 | $205K | |
| 2023 | 26,441 | $230K | |
| 2024incomplete | 15,852 | $110K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 9,081 | 7,475 | $277K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 6,404 | 5,594 | $146K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 4,941 | 3,589 | $127K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 7.8% | 4,163 | 1,510 | $92K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 2,066 | 1,396 | $69K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.6% | 9,997 | 3,279 | $65K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.2% | 3,811 | 1,283 | $61K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 3.8% | 2,720 | 1,071 | $44K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 1,804 | 1,022 | $37K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 2,057 | 1,362 | $23K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 475 | 416 | $18K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.3% | 441 | 402 | $15K |
123 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,107 | $14K |
| G0378 | Hospital observation service, per hour | 1.2% | 698 | $14K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 5,760 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,888 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,374 | $9K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 852 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,830 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 570 | $7K |
| 80053 | Comprehensive metabolic panel | <1% | 10,438 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,722 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 528 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,448 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,319 | $4K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 220 | $4K |
| 81001 | <1% | 3,857 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,078 | $3K |
| 86140 | <1% | 1,554 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,983 | $3K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 164 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,311 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,010 | $3K |
| 87081 | <1% | 426 | $3K | |
| 83690 | <1% | 2,649 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,062 | $3K |
| 97162 | <1% | 224 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $2K |
| 80061 | Lipid panel | <1% | 1,834 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,818 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 54 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,956 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 495 | $2K |
| 73610 | <1% | 194 | $2K | |
| 81025 | <1% | 1,519 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 202 | $2K |
| 84703 | <1% | 585 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 23 | $1K |
| 85027 | <1% | 3,183 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,770 | $1K |
| 87186 | <1% | 548 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 478 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 73 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,887 | $925.72 |
| 80306 | <1% | 1,342 | $920.24 | |
| 84484 | <1% | 2,294 | $914.93 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 280 | $904.32 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 122 | $765.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 278 | $762.73 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 276 | $762.59 |
| 87077 | <1% | 657 | $732.30 | |
| 83735 | <1% | 2,703 | $709.72 | |
| 81003 | <1% | 2,743 | $709.51 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 885 | $661.40 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,681 | $624.17 |
| 87088 | <1% | 267 | $610.34 | |
| 97161 | <1% | 83 | $608.40 | |
| 85730 | <1% | 490 | $559.69 | |
| 73630 | <1% | 75 | $554.40 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,181 | $538.98 |
| 83605 | <1% | 441 | $515.44 | |
| 85610 | <1% | 2,124 | $448.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 497 | $437.65 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,025 | $414.37 |
| 87486 | <1% | 198 | $401.49 | |
| 87581 | <1% | 199 | $401.49 | |
| 87807 | <1% | 44 | $389.32 | |
| 82728 | <1% | 444 | $371.52 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $320.92 |
| 97035 | <1% | 278 | $273.91 | |
| 85379 | <1% | 167 | $260.30 | |
| 84100 | <1% | 414 | $251.88 | |
| 73110 | <1% | 74 | $231.21 | |
| 85651 | <1% | 218 | $228.06 | |
| 73030 | <1% | 93 | $220.32 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 963 | $185.32 |
| J2704 | Injection, propofol, 10 mg | <1% | 244 | $180.35 |
| 82077 | <1% | 354 | $180.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13 | $166.03 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 661 | $157.40 |
| 84439 | <1% | 27 | $151.74 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 132 | $150.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 62 | $136.61 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 124 | $121.24 |
| 96376 | <1% | 255 | $118.80 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 395 | $115.20 |
| 82607 | <1% | 211 | $99.00 | |
| 85652 | <1% | 78 | $89.70 | |
| 83540 | <1% | 131 | $86.22 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 42 | $86.13 |
| 84145 | <1% | 57 | $73.84 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 69 | $60.29 |
| 87420 | <1% | 13 | $51.57 | |
| 73502 | <1% | 39 | $31.41 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 234 | $26.44 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 33 | $14.79 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 18 | $13.49 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 207 | $1.95 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 44 | $1.42 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 145 | $0.00 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 0% | 18 | $0.00 |
| 83880 | 0% | 507 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 260 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 260 | $0.00 |
| J3490 | Unclassified drugs | 0% | 29 | $0.00 |
| 82746 | 0% | 26 | $0.00 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 0% | 12 | $0.00 |
| 0012A | 0% | 121 | $0.00 | |
| 83550 | 0% | 40 | $0.00 | |
| 0011A | 0% | 168 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 19 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 24 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 26 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 26 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 15 | $0.00 |
| 80320 | 0% | 18 | $0.00 | |
| 73130 | 0% | 17 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 99 | $0.00 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 262 | $0.00 |
| 90715 | 0% | 14 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 662 | $0.00 |
| 73562 | 0% | 59 | $0.00 | |
| 85014 | 0% | 12 | $0.00 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 21 | $0.00 |
| 80076 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOWE, BREN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Livingston Healthcare Urgent Care | Livingston, MT | $512K |
| Livingston Healthcare | Livingston, MT | $4K |
| Livingston Healthcare | Wilsall, MT | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.